• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

烷化剂抗癌药物及其与微小RNA的关系。

Alkylating anticancer agents and their relations to microRNAs.

作者信息

Biersack Bernhard

机构信息

Organic Chemistry Laboratory, University of Bayreuth, Bayreuth 95440, Germany.

出版信息

Cancer Drug Resist. 2019 Mar 19;2(1):1-17. doi: 10.20517/cdr.2019.09. eCollection 2019.

DOI:10.20517/cdr.2019.09
PMID:35582140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9019174/
Abstract

Alkylating agents represent an important class of anticancer drugs. The occurrence and emergence of tumor resistance to the treatment with alkylating agents denotes a severe problem in the clinics. A detailed understanding of the mechanisms of activity of alkylating drugs is essential in order to overcome drug resistance. In particular, the role of non-coding microRNAs concerning alkylating drug activity and resistance in various cancers is highlighted in this review. Both synthetic and natural alkylating agents, which are approved for cancer therapy, are discussed concerning their interplay with microRNAs.

摘要

烷化剂是一类重要的抗癌药物。肿瘤对烷化剂治疗产生耐药性的出现和发生是临床上的一个严重问题。深入了解烷化剂的作用机制对于克服耐药性至关重要。特别是，本综述强调了非编码微小RNA在各种癌症中对烷化剂活性和耐药性的作用。本文讨论了已获批用于癌症治疗的合成和天然烷化剂与微小RNA的相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b1/9019174/b5f6f8d25c5c/cdr-2-1.fig.4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b1/9019174/cfc3ab3cb790/cdr-2-1.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b1/9019174/af2e7c8f2221/cdr-2-1.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b1/9019174/d1b72223fc47/cdr-2-1.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b1/9019174/b5f6f8d25c5c/cdr-2-1.fig.4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b1/9019174/cfc3ab3cb790/cdr-2-1.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b1/9019174/af2e7c8f2221/cdr-2-1.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b1/9019174/d1b72223fc47/cdr-2-1.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b1/9019174/b5f6f8d25c5c/cdr-2-1.fig.4.jpg

相似文献

1
Alkylating anticancer agents and their relations to microRNAs.烷化剂抗癌药物及其与微小RNA的关系。
Cancer Drug Resist. 2019 Mar 19;2(1):1-17. doi: 10.20517/cdr.2019.09. eCollection 2019.
2
Nitrosoureas: a review of experimental antitumor activity.亚硝基脲类：实验性抗肿瘤活性综述
Cancer Treat Rep. 1976 Jun;60(6):665-98.
3
From old alkylating agents to new minor groove binders.从旧的烷化剂到新的小沟结合剂。
Crit Rev Oncol Hematol. 2014 Jan;89(1):43-61. doi: 10.1016/j.critrevonc.2013.07.006. Epub 2013 Aug 20.
4
Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy.烷化剂，鲜有人走的路，改变抗癌疗法。
Anticancer Agents Med Chem. 2022;22(8):1478-1495. doi: 10.2174/1871520621666210811105344.
5
Mechanisms of resistance to alkylating agents.烷基化试剂耐药机制。
Cytotechnology. 1998 Sep;27(1-3):165-73. doi: 10.1023/A:1008060720608.
6
Nitrogen Mustards as Alkylating Agents: A Review on Chemistry, Mechanism of Action and Current USFDA Status of Drugs.氮芥类烷化剂：化学、作用机制和美国 FDA 药物现状综述。
Anticancer Agents Med Chem. 2019;19(9):1080-1102. doi: 10.2174/1871520619666190305141458.
7
Small-molecule based delivery systems for alkylating antineoplastic compounds.用于烷基化抗肿瘤化合物的小分子递送系统。
ChemMedChem. 2008 Apr;3(4):536-42. doi: 10.1002/cmdc.200700229.
8
[Alkylating agents].[烷化剂]
Bull Cancer. 2011 Nov;98(11):1237-51. doi: 10.1684/bdc.2011.1471.
9
Patterns of resistance and therapeutic synergism among alkylating agents.烷化剂之间的耐药模式及治疗协同作用。
Antibiot Chemother (1971). 1978;23:200-15. doi: 10.1159/000401484.
10
Modulating MGMT expression through interfering with cell signaling pathways.通过干扰细胞信号通路调节 MGMT 表达。
Biochem Pharmacol. 2023 Sep;215:115726. doi: 10.1016/j.bcp.2023.115726. Epub 2023 Jul 29.

引用本文的文献

1
Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles.纳米颗粒和基于壳聚糖的纳米颗粒在抗癌药物递送方面的进展。
Int J Pharm X. 2024 Aug 28;8:100281. doi: 10.1016/j.ijpx.2024.100281. eCollection 2024 Dec.
2
Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents.NCI-60 细胞系数据的多组学分析揭示了与烷基化抗癌药物耐药性相关的新型代谢过程。
Int J Mol Sci. 2023 Aug 26;24(17):13242. doi: 10.3390/ijms241713242.
3
Epigenetic basis of cancer drug resistance.

本文引用的文献

1
Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs.抗癌活性铂配合物与非编码RNA/微小RNA之间的相互作用。
Noncoding RNA Res. 2016 Oct 13;2(1):1-17. doi: 10.1016/j.ncrna.2016.10.001. eCollection 2017 Mar.
2
Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway.miR-299-5p 抑制通过 MAPK/ERK 信号通路增强胶质母细胞瘤细胞对替莫唑胺的敏感性。
Biosci Rep. 2018 Sep 12;38(5). doi: 10.1042/BSR20181051. Print 2018 Oct 31.
3
MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation.
癌症耐药性的表观遗传基础。
Cancer Drug Resist. 2020 Mar 19;3(1):113-116. doi: 10.20517/cdr.2020.06. eCollection 2020.
miRNA-181d 的表达水平对卡莫司汀植入剂治疗反应有显著影响。
Neurosurgery. 2019 Jul 1;85(1):147-155. doi: 10.1093/neuros/nyy214.
4
MicroRNA-30a increases the chemosensitivity of U251 glioblastoma cells to temozolomide by directly targeting beclin 1 and inhibiting autophagy.微小RNA-30a通过直接靶向自噬相关蛋白1（beclin 1）并抑制自噬来增加U251胶质母细胞瘤细胞对替莫唑胺的化学敏感性。
Exp Ther Med. 2018 Jun;15(6):4798-4804. doi: 10.3892/etm.2018.6007. Epub 2018 Mar 29.
5
MicroRNA-142-3p is involved in regulation of expression in glioblastoma cells.微小RNA-142-3p参与胶质母细胞瘤细胞中基因表达的调控。
Cancer Manag Res. 2018 Apr 12;10:775-785. doi: 10.2147/CMAR.S157261. eCollection 2018.
6
Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.氮芥作为烷化抗癌药物的治疗历程：从历史到未来展望。
Eur J Med Chem. 2018 May 10;151:401-433. doi: 10.1016/j.ejmech.2018.04.001. Epub 2018 Apr 3.
7
Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression.miR-4319 的再表达通过抑制 Her-2 抑制前列腺癌的生长。
Clin Transl Oncol. 2018 Nov;20(11):1400-1407. doi: 10.1007/s12094-018-1871-y. Epub 2018 Apr 9.
8
MicroRNA-1294 inhibits the proliferation and enhances the chemosensitivity of glioma to temozolomide via the direct targeting of TPX2.微小RNA-1294通过直接靶向TPX2抑制胶质瘤的增殖并增强其对替莫唑胺的化学敏感性。
Am J Cancer Res. 2018 Feb 1;8(2):291-301. eCollection 2018.
9
Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31 levels.磷酸雌莫司汀通过下调 miR-31 水平诱导前列腺癌细胞系 PC3 凋亡。
Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):40-45. doi: 10.26355/eurrev_201801_14098.
10
MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression.miR-21 通过降低 Spry2 表达增强胶质母细胞瘤细胞对卡莫司汀的耐药性。
Eur Rev Med Pharmacol Sci. 2017 Nov;21(22):5065-5071. doi: 10.26355/eurrev_201711_13819.